U.S. Stock Movement | Due to competitor's drug development falling short of targets, Vertex Pharmaceuticals (VRTX.US) rose nearly 7%.

According to the Zhiyuan Finance APP, on Monday, Vertex Pharmaceuticals (VRTX.US) soared nearly 7% in early trading, reaching an all-time high; meanwhile, its competitor Sionna Therapeutics (SION.US) plummeted over 90%, hitting a record low. SION announced that it would terminate the development of its experimental cystic fibrosis drug SION-719, as it failed to meet primary endpoints in its mid-stage clinical trial. Investors had previously worried that SION could pose a threat to VRTX's core cystic fibrosis business, but the failure of this trial has alleviated those concerns.